文献速递儿童青少年精神

巴洛伐普坦治疗儿童孤独症谱系障碍社交沟通障碍的随机临床试验

Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2022-01-01

该随机双盲安慰剂对照2期试验纳入5至17岁、IQ≥70的孤独症谱系障碍患者,比较巴洛伐普坦(成人等效10mg)与安慰剂对社交沟通的疗效。第24周Vineland-II两域复合评分较基线变化无显著差异,次要终点亦无改善,巴洛伐普坦耐受性良好。

要点

  • 巴洛伐普坦组与安慰剂组第24周Vineland-II 2DC评分变化无显著差异。
  • 所有次要终点在第24周均未观察到巴洛伐普坦优于安慰剂的改善。
  • 巴洛伐普坦耐受性良好,不良事件与严重不良事件比例两组相似。

核心结论

  • 在儿童孤独症谱系障碍患者中,巴洛伐普坦未能改善社交与沟通功能。
  • 巴洛伐普坦在5岁及以上儿童中耐受性良好。

研究设计与样本

  • aV1ation研究为随机、双盲、24周、平行组、安慰剂对照2期试验,在美国41个中心开展。
  • 参与者随机接受每日4mg或10mg成人等效剂量巴洛伐普坦或安慰剂,直至4mg组终止。
  • 主要疗效分析人群为接受年龄校正后相当于10mg成人剂量巴洛伐普坦的参与者与同期随机分配的安慰剂组参与者。

主要发现

  • 共筛查599人,339人被随机分配至4mg巴洛伐普坦成人等效剂量组(91人[26.8%])、10mg巴洛伐普坦成人等效剂量组(126人[37.2%])或安慰剂组(122人[36.0%])。
  • 主要分析纳入86名10mg巴洛伐普坦成人等效剂量组参与者和81名安慰剂组参与者(平均[SD]年龄12.1[3.4]岁;139名男性[83.2%])。
  • 第24周所有次要终点均未观察到巴洛伐普坦较安慰剂的改善。
  • 不良事件报告比例:巴洛伐普坦组66/86(76.7%)vs 安慰剂组61/81(75.3%);严重不良事件:巴洛伐普坦组1/86(1.2%)vs 安慰剂组4/81(4.9%)。

关键数值与推荐

  • 主要终点为第24周Vineland-II两域复合(2DC;社交与沟通域)评分较基线的变化。

临床怎么用

  • 在本试验人群中,巴洛伐普坦未显示改善社交与沟通的疗效。
  • 巴洛伐普坦在5岁及以上儿童中耐受性良好,未出现新的安全性问题。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There are no approved medications for the core symptoms of autism spectrum disorder (ASD), socialization and communication difficulties. OBJECTIVE: To evaluate the efficacy and safety of balovaptan, an oral selective vasopressin 1a receptor antagonist, compared with placebo in children and adolescents with ASD. DESIGN, SETTING, AND PARTICIPANTS: The aV1ation study was a randomized, double-blind, 24-week, parallel-group, placebo-controlled phase 2 trial. Between November 22, 2016, and September 3, 2019, individuals were screened and randomly assigned to treatment groups. The primary efficacy analysis population comprised participants taking age-adjusted balovaptan equivalent to a 10-mg adult dose and participants from the concurrently randomized placebo group. This multicenter trial took place across 41 sites in the US. Participants were aged 5 to 17 years with diagnosed ASD and an IQ of 70 or greater. Data were analyzed from April 8 to November 16, 2020. INTERVENTIONS: Participants were randomly assigned to daily 4-mg or 10-mg adult-equivalent balovaptan or placebo, until the 4-mg group was discontinued. MAIN OUTCOMES AND MEASURES: The primary end point was change from baseline on the Vineland-II two-domain composite (2DC; socialization and communication domains) score at week 24. RESULTS: Between November 2016 and September 2019, a total of 599 individuals were screened and 339 participants were randomly assigned to receive 4-mg balovaptan adult-equivalent dose (91 [26.8%]), 10-mg balovaptan adult-equivalent dose (126 [37.2%]), or placebo (122 [36.0%]). Primary analysis included 86 participants assigned to receive 10-mg balovaptan adult-equivalent dose and 81 assigned to receive placebo (mean [SD] age, 12.1 [3.4] years; 139 male participants [83.2%]). No statistically significant differences were observed between the balovaptan and placebo groups in change from baseline on the Vineland-II 2DC score at week 24 (difference in adjusted least-squares mean, -0.16; 90% CI, -2.56 to 2.23; P = .91). No improvements for balovaptan vs placebo were observed at week 24 for any secondary end points. Balovaptan was well tolerated with no emerging safety concerns. Similar proportions of participants reported adverse events (balovaptan, 66 of 86 [76.7%] vs placebo, 61 of 81 [75.3%]) and serious adverse events (balovaptan, 1 of 86 [1.2%] vs placebo, 4 of 81 [4.9%]). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, balovaptan did not demonstrate efficacy in improvement of socialization and communication in this population with pediatric ASD. Balovaptan was well tolerated in children 5 years or older. Further development of robust, sensitive, and objective outcome measures may help to improve future studies in the assessment of therapies targeting communication and socialization in pediatric ASD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02901431.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hollander E, Jacob S, Jou R, et al. Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022. PMID: 35793101. doi:10.1001/jamapsychiatry.2022.1717

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。